Global X Genomics & Biotechnology ETFGNOM
Type
ETF
Peer group
US equity: Healthcare
Net assets
$52.4M
Expense ratio
0.50%
1-year return
+78.6%
3 years, a year
+13.5%
5 years, a year
-7.4%
12-month yield
0.92%
Holdings
51
What it aims to do.
"The Global X Genomics & Biotechnology ETF (""Fund"") seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Solactive Genomics Index (""Underlying Index"")."
Top 10 holdings.
| Holding | % of fund |
|---|---|
| MRNA Moderna, Inc. | 7.86% |
| PRAX Praxis Precision Medicines Inc | 6.24% |
| ARWR Arrowhead Pharmaceuticals, Inc. | 5.69% |
| ILMN Illumina, Inc. | 5.13% |
| GH Guardant Health, Inc. | 4.71% |
| VRTX Vertex Pharmaceuticals Incorporated | 4.32% |
| BMRN Biomarin Pharmaceutical Inc. | 4.31% |
| NTRA Natera, Inc. | 3.91% |
| BNTX BioNTech SE | 3.87% |
| Avidity Biosciences Inc | 3.75% |
More on GNOM.
- GNOM overview
- GNOM holdings
- GNOM risk
- GNOM costs
- GNOM money in and out
- GNOM share classes
- Compare GNOM with other funds
Returns after fees, from the fund's SEC filings up to Aug 2026. Past returns are not a promise. Not financial advice.